



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

CERTIFICATION EXAMINATION IN PSYCHIATRY

The American Board of Psychiatry and Neurology, Inc. (ABPN) is a not-for-profit corporation dedicated to serving the public interest and the professions of psychiatry and neurology by promoting excellence in practice through certification and continuing certification processes.

The ABPN designs and develops the psychiatry certification examination to assess the knowledge and reasoning skills needed to provide high quality patient care in the broad domain of the specialty. It utilizes two-dimensional content specifications. Within the two-dimensional format, one dimension is comprised of disorders and topics while the other is comprised of competencies and mechanisms that cut across the various disorders of the first dimension. By design, the two dimensions are interrelated and not independent of each other. All of the questions on the examination will fall into one of the disorders/topics and will be aligned with a competency/mechanism. For example, an item on substance use could focus on treatment, or it could focus on systems-based practice.

Candidates should use the detailed content specifications as a guide to prepare for a certification examination. Scores for these examinations will be reported in a standardized format rather than the previous percent correct format.

For more information, please contact us at questions@abpn.org or visit our website at www.abpn.org.



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

CERTIFICATION EXAMINATION IN PSYCHIATRY Content Blueprint

| Number of questions: 425 | | |
|---|--|-------|
| Dimension 1 | | |
| Psychiatric Disorders and Topics | | |
| 01. | Developmental processes and development through the life cycle | 2-4% |
| 02. | Neurodevelopmental disorders | 3-5% |
| 03. | Substance-related and addictive disorders | 7-11% |
| 04. | Schizophrenia spectrum and other psychotic disorders | 8-12% |
| 05. | Depressive disorders | 8-12% |
| 06. | Bipolar and related disorders | 4-6% |
| 07. | Anxiety disorders | 7-9% |
| 08. | Obsessive-compulsive and related disorders | 2-4% |
| 09. | Trauma- and stressor-related disorders | 4-6% |
| 10. | Dissociative disorders | 1-2% |
| 11. | Somatic symptom and related disorders | 2-4% |
| 12. | Feeding and eating disorders | 2-4% |
| 13. | Elimination disorders | 1-2% |
| 14. | Sleep-wake disorders | 3-5% |
| 15. | Sexual dysfunctions | 1-3% |
| 16. | Gender dysphoria | 1-2% |
| 17. | Disruptive, impulse-control, and conduct disorders | 1-3% |
| 18. | Personality disorders | 5-7% |
| 19. | Paraphilic disorders | 1-2% |
| 20. | Other conditions that may be a focus of clinical attention | 1-3% |
| 21. | Neurocognitive disorders | 6-8% |
| 22. | Neurologic disorders | 4-6% |
| 23. | Forensic psychiatry | 1-2% |
| 24. | Dimension 2 topics without a corresponding Dimension 1 topic | 3-5% |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

CERTIFICATION EXAMINATION IN PSYCHIATRY Content Blueprint

| | | |
|--|--|--------|
| Number of questions: 425 | | |
| Dimension 2 | | |
| Physician Competencies and Mechanisms | | |
| A. | Neuroscience and mechanisms of disease | 17-23% |
| B. | Behavioral/social sciences and psychosocial mechanisms of diseases | 4-6% |
| C. | Clinical aspects of psychiatric and neuropsychiatric disorders | 17-23% |
| D. | Diagnostic procedures | 8-12% |
| E. | Treatment | 25-35% |
| F. | Interpersonal and communication skills | 2-4% |
| G. | Professionalism, ethics, and the law | 3-5% |
| H. | Practice-based learning and improvement | 3-5% |
| I. | Systems-based practice | 3-5% |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

CERTIFICATION EXAMINATION IN PSYCHIATRY Content Outline

| Dimension 1 |
|--|
| Psychiatric Disorders and Topics |
| 01. Developmental processes and development through the life cycle (psychiatry and neurology) |
| a. Infancy through adolescence |
| i. Personality and other developmental processes |
| a. Child development theory (e.g., cognitive theory, moral development, learning theory, psychodynamics) |
| b. Development of gender identity and sexual orientation |
| ii. Psychosocial influences |
| iii. Other |
| b. Adulthood |
| i. Personality adaptation and other developmental processes |
| ii. Psychosocial influences |
| iii. Acquisition and loss of specific capacities |
| iv. Other |
| c. Late life |
| i. Personality adaptation and other developmental processes |
| ii. Psychosocial influences |
| a. Life course – developmental and transitional events (retirement, death of a spouse) |
| iii. Acquisition and loss of specific capacities |
| a. Systemic, anatomic, and physiologic changes |
| b. Psychological changes |
| c. Other |
| iv. Other |
| 02. Neurodevelopmental disorders |
| a. Intellectual developmental disorder (intellectual disability) |
| b. Language disorder |
| c. Speech sound disorder |
| d. Childhood-onset fluency disorder (stuttering) |
| e. Social (pragmatic) communication disorder |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| f. Autistic spectrum disorder |
| g. Attention deficit/hyperactivity disorder |
| h. Specific learning disorder |
| i. Developmental coordination disorder |
| j. Stereotypic movement disorder |
| k. Tourette disorder |
| l. Persistent (chronic) motor or vocal tic disorder |
| m. Provisional tic disorder |
| 03. Substance-related and addictive disorders |
| a. Alcohol-related disorders |
| b. Caffeine-related disorders |
| c. Cannabis-related disorders |
| d. Phencyclidine disorder |
| e. Other hallucinogen-related disorders |
| f. Inhalant-related disorders |
| g. Opioid-related disorders |
| h. Sedative-, hypnotic-, or anxiolytic-related disorders |
| i. Stimulant-related disorders |
| j. Tobacco-related disorders |
| k. Other (or unknown) substance-related disorders |
| l. Gambling disorder |
| 04. Schizophrenia spectrum and other psychotic disorders |
| a. Delusional disorder |
| b. Brief psychotic disorder |
| c. Schizophreniform disorder |
| d. Schizophrenia |
| e. Schizoaffective disorder |
| f. Substance/medication-induced psychotic disorder |
| g. Psychotic disorder due to another medical condition |
| h. Catatonia |
| i. Catatonic disorder due to another medical condition |
| j. Unspecified catatonia |
| k. Other specified schizophrenia spectrum and other psychotic disorder |
| l. Unspecified schizophrenia spectrum and other psychotic disorder |
| 05. Depressive disorders |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| a. Disruptive mood dysregulation disorder |
| b. Major depressive disorder |
| c. Persistent depressive disorder (dysthymia) |
| d. Premenstrual dysphoric disorder |
| e. Substance/medication-induced depressive disorder |
| f. Depressive disorder due to another medical condition |
| g. Other specified depressive disorder |
| h. Unspecified depressive disorder |
| i. Unspecified mood disorder |
| 06. Bipolar and related disorders |
| a. Bipolar I disorder |
| b. Bipolar II disorder |
| c. Cyclothymic disorder |
| d. Substance/medication-induced bipolar and related disorders |
| e. Bipolar and related disorder due to another medical condition |
| f. Other specified bipolar and related disorder |
| g. Unspecified bipolar and related disorder |
| 07. Anxiety disorders |
| a. Separation anxiety disorder |
| b. Selective mutism |
| c. Specific phobia |
| d. Social anxiety disorder |
| e. Panic disorder |
| f. Agoraphobia |
| g. Generalized anxiety disorder |
| h. Substance/medication-induced anxiety disorder |
| i. Anxiety disorder due to another medical condition |
| j. Other specified anxiety disorder |
| k. Unspecified anxiety disorder |
| 08. Obsessive-compulsive and related disorders |
| a. Obsessive-compulsive disorder |
| b. Body dysmorphic disorder |
| c. Hoarding disorder |
| d. Trichotillomania (hair-pulling disorder) |
| e. Excoriation (skin-picking) disorder |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|---|
| f. Substance/medication-induced obsessive-compulsive and related disorder |
| g. Obsessive-compulsive and related disorder due to another medical condition |
| h. Other specified obsessive-compulsive and related disorder |
| i. Unspecified obsessive-compulsive and related disorder |
| 09. Trauma- and stressor-related disorders |
| a. Reactive attachment disorder |
| b. Disinhibited social engagement disorder |
| c. Posttraumatic stress disorder |
| d. Acute stress disorder |
| e. Adjustment disorders |
| f. Prolonged grief disorder |
| g. Other specified trauma- and stressor-related disorder |
| h. Unspecified trauma- and stressor-related disorder |
| 10. Dissociative disorders |
| a. Dissociative identity disorder |
| b. Dissociative amnesia |
| c. Depersonalization/derealization disorder |
| d. Other specified dissociative disorder |
| e. Unspecified dissociative disorder |
| 11. Somatic symptom and related disorders |
| a. Somatic symptom disorder |
| b. Illness anxiety disorder |
| c. Functional neurological symptom disorder (conversion disorder) |
| d. Psychological factors affecting other medical conditions |
| e. Factitious disorder |
| f. Other specified somatic symptom and related disorder |
| g. Unspecified somatic symptom and related disorder |
| 12. Feeding and eating disorders |
| a. Pica |
| b. Rumination disorder |
| c. Avoidant/restrictive food intake disorder |
| d. Anorexia nervosa |
| e. Bulimia nervosa |
| f. Binge-eating disorder |
| g. Other specified feeding or eating disorder |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| h. Unspecified feeding or eating disorder |
| 13. Elimination disorders |
| a. Enuresis |
| b. Encopresis |
| c. Other specified elimination disorder |
| d. Unspecified elimination disorder |
| 14. Sleep-wake disorders |
| a. Insomnia disorder |
| b. Hypersomnolence disorder |
| c. Narcolepsy |
| d. Obstructive sleep apnea hypopnea |
| e. Central sleep apnea |
| f. Sleep-related hypoventilation |
| g. Circadian rhythm sleep-wake disorders |
| h. Non-REM sleep arousal disorders |
| i. Nightmare disorder |
| j. REM sleep behavior disorder |
| k. Restless legs syndrome |
| l. Substance/medication-induced sleep disorder |
| m. Other specified insomnia disorder |
| n. Unspecified insomnia disorder |
| o. Other specified hypersomnolence disorder |
| p. Unspecified hypersomnolence disorder |
| q. Other specified sleep-wake disorder |
| r. Unspecified sleep-wake disorder |
| 15. Sexual dysfunctions |
| a. Delayed ejaculation |
| b. Erectile disorder |
| c. Female orgasmic disorder |
| d. Female sexual interest/arousal disorder |
| e. Genito-pelvic pain/penetration disorder |
| f. Male hypoactive sexual desire disorder |
| g. Premature (early) ejaculation |
| h. Substance/medication-induced sexual dysfunction |
| i. Other specified sexual dysfunction |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| j. Unspecified sexual dysfunction |
| 16. Gender dysphoria |
| a. Other specified gender dysphoria |
| b. Unspecified gender dysphoria |
| 17. Disruptive, impulse-control, and conduct disorders |
| a. Oppositional defiant disorder |
| b. Intermittent explosive disorder |
| c. Conduct disorder |
| d. Pyromania |
| e. Kleptomania |
| f. Other specified disruptive, impulse-control, and conduct disorder |
| g. Unspecified disruptive, impulse-control and conduct disorder |
| 18. Personality disorders |
| a. Paranoid personality disorder |
| b. Schizoid personality disorder |
| c. Schizotypal personality disorder |
| d. Antisocial personality disorder |
| e. Borderline personality disorder |
| f. Histrionic personality disorder |
| g. Narcissistic personality disorder |
| h. Avoidant personality disorder |
| i. Dependent personality disorder |
| j. Obsessive-compulsive personality disorder |
| k. Personality change due to another medical condition |
| l. Other specified personality disorder |
| m. Unspecified personality disorder |
| n. General personality disorder |
| 19. Paraphilic disorders |
| a. Voyeuristic disorder |
| b. Exhibitionistic disorder |
| c. Frotteuristic disorder |
| d. Sexual masochism disorder |
| e. Sexual sadism disorder |
| f. Pedophilic disorder |
| g. Fetishistic disorder |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|---|
| h. Transvestic disorder |
| i. Other specified paraphilic disorder |
| j. Unspecified paraphilic disorder |
| 20. Other conditions that may be a focus of clinical attention |
| 21. Neurocognitive disorders |
| a. Delirium |
| b. Other specified delirium |
| c. Unspecified delirium |
| d. Major or mild neurocognitive disorder due to Alzheimer disease |
| e. Major or mild frontotemporal neurocognitive disorder |
| f. Major or mild neurocognitive disorder with Lewy bodies |
| g. Major or mild vascular neurocognitive disorder |
| h. Major or mild neurocognitive disorder due to traumatic brain injury |
| i. Substance/medication-induced major or mild neurocognitive disorder |
| j. Major or mild neurocognitive disorder due to HIV infection |
| k. Major or mild neurocognitive disorder due to prion disease |
| l. Major or mild neurocognitive disorder due to Parkinson disease |
| m. Major or mild neurocognitive disorder due to Huntington disease |
| n. Major or mild neurocognitive disorder due to another medical condition |
| o. Major or mild neurocognitive disorder due to multiple etiologies |
| p. Unspecified neurocognitive disorder |
| 22. Neurologic disorders |
| a. Infections of the nervous system |
| b. Vascular diseases |
| c. Disorders of cerebrospinal and brain fluids |
| d. Neuro-oncology |
| e. Trauma |
| f. Birth injuries and developmental abnormalities |
| g. Genetic diseases of recognized biochemical abnormality |
| h. Cerebral degenerations of childhood |
| i. Cranial nerve disorders |
| j. Peripheral neuropathies |
| k. Ataxias |
| l. Headache |
| m. Movement disorders |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|---|
| n. Spinal cord diseases |
| o. Neuromuscular junction disorders |
| p. Myopathies |
| q. Demyelinating diseases |
| r. Epilepsy and episodic disorders |
| s. Neurologic complications of systemic diseases |
| t. Neurotoxicology |
| u. Pain syndromes |
| v. Other |
| 23. Forensic psychiatry |
| a. Legal regulation of psychiatry |
| b. Civil |
| c. Criminal |
| d. Death penalty |
| e. Correction/correctional healthcare |
| f. Legal system/basic law |
| g. Children/families |
| h. Special issues in forensic psychiatry |
| 24. Dimension 2 topics without a corresponding Dimension 1 topic |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| Dimension 2 |
|---|
| Physician Competencies and Mechanisms |
| A. Neuroscience and mechanisms of disease |
| I. Neuroanatomy |
| II. Cellular and molecular neurobiology |
| III. Neuropathology |
| IV. Genetics |
| V. Neurochemistry |
| VI. Neurophysiology |
| VII. Chronobiology (e.g., biological rhythms, sleep) |
| VIII. Neuroendocrinology and neuroimmunology |
| IX. Other |
| B. Behavioral/social sciences and psychosocial mechanisms of diseases |
| I. Psychology |
| i. Experimental and behavioral psychology |
| ii. Neuropsychology, cognitive psychology |
| iii. Social psychology |
| iv. Psychoanalytic and psychodynamic psychology |
| v. Other |
| II. Sociology |
| III. Anthropology, culture, ethnicity, race, and spirituality |
| IV. Biostatistics |
| V. Research design |
| VI. Other |
| VII. Normal development |
| C. Clinical aspects of psychiatric and neuropsychiatric disorders |
| I. Epidemiology |
| II. Factors affecting psychiatric and neuropsychiatric disorders (predisposing, protective, and perpetuating factors, precipitants) |
| III. Clinical presentation, symptoms, and signs |
| IV. Comorbidity |
| V. Differential diagnosis |
| VI. Prognosis and course of illness |
| D. Diagnostic procedures |
| I. General physical and neurological examination |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| II. Psychiatric interview and mental status examination |
| III. Psychological testing |
| IV. Neuropsychological testing |
| V. Diagnostic assessments and rating scales |
| VI. Laboratory testing |
| VII. Neuroimaging |
| VIII. EEG |
| IX. Sleep Studies |
| X. Neurophysiologic testing |
| XI. Other |
| E. Treatment |
| I. General treatment planning and decision making |
| II. General principles of psychopharmacology and neuropharmacology |
| i. Pharmacokinetics/pharmacodynamics |
| ii. Drug interactions |
| iii. Age, gender, and ethnicity issues |
| iv. Genomics |
| III. Specific pharmacologic agents |
| i. Tricyclics and heterocyclics |
| ii. Monoamine oxidase inhibitors |
| iii. Selective serotonin reuptake inhibitors (SSRI) |
| iv. Selective norepinephrine reuptake inhibitors (NRI) |
| v. Selective serotonin-norepinephrine reuptake inhibitors (SNRI) |
| vi. Other antidepressants |
| vii. Lithium |
| viii. Anticonvulsants |
| ix. Benzodiazepines |
| x. Beta blockers |
| xi. Alpha agonists |
| xii. Typical antipsychotics |
| xiii. Atypical antipsychotics |
| xiv. Psychostimulants |
| xv. Hypnotics and sedatives |
| xvi. Cognitive enhancers |
| xvii. Calcium channel blockers |
| xviii. Dopamine agonists (including L-DOPA) |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| xix. Anticholinergics |
| xx. Opioid agonists/antagonists |
| xxi. Other agents used in the management of psychiatric disorders |
| xxii. Other agents used in the management of neurologic disorders |
| xxiii. Other agents used in the management of other medical disorders |
| IV. Treatment of substance-related and addictive disorders |
| i. Pharmacologic |
| a. Management of use (disorder), intoxication, and withdrawal |
| b. Relapse prevention |
| c. Management of co-occurring conditions |
| ii. Nonpharmacologic |
| a. Management of use (disorder), intoxication, and withdrawal |
| b. Relapse prevention |
| c. Management of co-occurring conditions |
| V. Treatment of aggression/self-injury |
| i. Pharmacologic |
| ii. Nonpharmacologic |
| VI. Treatment of sleep-wake disorders |
| i. Pharmacologic |
| ii. Nonpharmacologic |
| VII. Treatment of pain |
| i. Pharmacologic |
| ii. Nonpharmacologic |
| VIII. Treatment of neuroleptic malignant syndrome, TDEPS, and serotonin syndrome |
| i. Pharmacologic |
| ii. Nonpharmacologic |
| IX. Pharmacotherapy in special situations |
| i. Renal disease |
| ii. Hepatic disease |
| iii. Pregnancy |
| iv. Breast-feeding |
| v. Tardive dyskinesia and extrapyramidal symptoms |
| X. Augmentation strategies |
| XI. Nonpharmacologic somatic treatment |
| i. Biofeedback |
| ii. Electroconvulsive therapy |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|---|
| iii. Phototherapy |
| iv. Chronotherapy |
| v. Vagal nerve stimulation |
| vi. rTMS (repetitive transcranial magnetic stimulation) |
| vii. Neurosurgical approaches |
| viii. Other |
| XII. Psychotherapy |
| i. Supportive |
| ii. Cognitive and/or behavioral |
| iii. Interpersonal |
| iv. Psychodynamic and psychoanalytic |
| v. Couples and family |
| vi. Group |
| vii. Crisis intervention (e.g. critical incident debriefing, psychological debriefing/early intervention) |
| viii. Motivational interviewing |
| ix. Other (e.g., hypnotherapy, sex therapy, mindfulness, meditation) |
| XIII. Psychosocial interventions |
| i. Psychoeducation |
| ii. Vocational and occupational rehabilitation |
| iii. Self-help groups (e.g., AA, NA) |
| iv. Community-based treatment programs (e.g., halfway houses, day hospitals, multimodal treatment programs, therapeutic communities, opioid agonist treatment programs) |
| v. Other |
| F. Interpersonal and communication skills |
| I. Communication with patients |
| II. Communication with other professionals |
| III. Communication with the public |
| IV. Communication with patients' families |
| V. Communication with the healthcare team |
| G. Professionalism, ethics, and the law |
| I. Sensitivity to diversity |
| II. Adherence to ethical principles (e.g., informed consent, research issues, clinical care) |
| III. Fatigue management, work-life balance, and physician well-being |
| IV. Professional behavior |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|---|
| V. Participation in the professional community |
| VI. Legal issues in psychiatry |
| VII. End of life issues |
| H. Practice-based learning and improvement |
| I. Development and execution of lifelong learning |
| i. Self-assessment and self-improvement |
| ii. Use of evidence in the clinical workflow |
| II. Formal practice-based quality improvement |
| I. Systems-based practice |
| I. Patient safety and the healthcare team |
| i. Medical errors, patient safety, quality improvement, and improvement activities |
| ii. Regulatory and educational activities related to patient safety |
| II. Resource management |
| i. Parity |
| ii. Access to care |
| iii. Telepsychiatry |
| III. Community-based care |
| i. Community based programs |
| a. Other (e.g. nursing homes, skilled nursing facilities, assisted living) |
| ii. Prevention |
| iii. Recovery and rehabilitation |
| iv. Integrated care (collaborative care) |
| IV. Consultation to nonpsychiatric medical providers and nonmedical systems (e.g., military, schools, businesses, forensic) |
| V. Public health and prevention, and public policy |
| VI. Documentation of practice, management of records, insurance, and reimbursement |